The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...

Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reacti ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection by a health care professional.